Sun.May 14, 2023

article thumbnail

Industry Voices—The case for hospitals to invest in cleaner air

Fierce Healthcare

Industry Voices—The case for hospitals to invest in cleaner air pminemyer Sun, 05/14/2023 - 23:25

Hospitals 129
article thumbnail

FDA advisors narrowly back Sarepta’s Duchenne gene therapy

pharmaphorum

FDA advisors narrowly back Sarepta’s Duchenne gene therapy Phil.

FDA 98
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Accelerated Delivery to a Development Candidate Enabled by RapidFire Mass Spectrometry

BioPharm

Time to results can be significantly reduced with the use of RapidFire high-throughput mass spectrometry (MS). With this technique, a lab’s next great innovation can be brought from conception to reality in a timely and efficient manner.

40
article thumbnail

After FDA snub, DBV charts a new course for Viaskin peanut

pharmaphorum

After FDA snub, DBV charts a new course for Viaskin peanut Phil.

FDA 52
article thumbnail

From Diagnosis to Delivery: How AI is Revolutionizing the Patient Experience

Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.

The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven

article thumbnail

LaNova Medicines Entered into an Exclusive License Agreement with AstraZeneca for LM-305 to Treat Multiple Myeloma

PharmaShots

Shots: LaNova Medicines will receive an up front and near-term fees of ~$55M and is eligible to receive additional development and commercial milestones of ~$545M along with royalties on net sales globally AstraZeneca to get an exclusive license globally to research, develop, and commercialize LM-305, a pre-clinical stage ADC targeting G protein-coupled receptor, class C, group 5, member D (GPRC5D) The collaboration focuses on discovering and developing innovative therapies in ADC and Immuno-Onc

40
article thumbnail

150+ Page Paperback MPJE Book For Less Than 5$ – Ending Soon!

Med Ed 101

A week ago or so I released the MPJE Master 2nd Edition Ebook. The PAPERBACK Edition is now available. You can literally get a 150+ page book for less than 5$. I will end this initial offer to my followers this week and the price will increase significantly. There are a ton of updates from […] The post 150+ Page Paperback MPJE Book For Less Than 5$ – Ending Soon!

40